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Sameer Sirohi, MSc,† Yemisi Solanke, BSc,† Eleanor Wood, MB BChir,‡ Adele Rowley, PhD,†
Steve Webber, PhD,† and Claire A. Walshe, PhD†
Background: Kinases are key mediators of inﬂammation, highlighting the potential of kinase inhibitors as treatments for inﬂammatory disorders.
Selective kinase inhibitors, however, have proved disappointing, particularly in the treatment of rheumatoid arthritis and inﬂammatory bowel disease.
Consequently, to improve efﬁcacy, attention has turned to multikinase inhibition.
Methods: The activity of a narrow spectrum kinase inhibitor, TOP1210, has been compared with selective kinase inhibitors (BIRB-796, dasatinib and
BAY-61-3606) in a range of kinase assays, inﬂammatory cell assays, and in inﬂamed biopsies from patients with ulcerative colitis (UC). Effects on
recombinant P38a, Src, and Syk kinase activities were assessed using Z-lyte assays (Invitrogen, Paisley, United Kingdom). Anti-inﬂammatory effects
were assessed by measurement of proinﬂammatory cytokine release from peripheral blood mononuclear cells, primary macrophages, HT29 cells,
inﬂamed colonic UC biopsies, and myoﬁbroblasts isolated from inﬂamed colonic UC mucosa.
Results: TOP1210 potently inhibits P38a, Src, and Syk kinase activities. Similarly, TOP1210 demonstrates potent inhibitory activity against proin-
ﬂammatory cytokine release in each of the cellular assays and the inﬂamed colonic UC biopsies and myoﬁbroblasts isolated from inﬂamed colonic UC
mucosa. Generally, the selective kinase inhibitors showed limited and weaker activity in the cellular assays compared with the broad inhibitory proﬁle of
TOP1210. However, combination of the selective inhibitors led to improved efﬁcacy and potency in both cellular and UC biopsy assays.
Conclusions: Targeted, multikinase inhibition with TOP1210 leads to a broad efﬁcacy proﬁle in both the innate and adaptive immune responses, with
signiﬁcant advantages over existing selective kinase approaches, and potentially offers a much improved therapeutic beneﬁt in inﬂammatory bowel disease.
(Inﬂamm Bowel Dis 2016;22:1306–1315)
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P rotein kinases are enzymes that catalyze the transfer of a phosphategroup from adenosine triphosphate (ATP) to a serine, threonine, or
tyrosine residue in their substrates. The protein kinase inhibitor ima-
tinib was ﬁrst approved for clinical use in 20011; since then, protein
kinases have become increasingly attractive therapeutic targets, with
over 150 drugs in clinical trials and 28 approved by the Food and
Drug Administration.2 Currently, most kinase inhibitors have been
approved for use in clinical oncology. However, many of the major
classes of immune cell receptors, including T-cell receptor, B-cell
receptor, natural killer–cell receptor, and Fc receptors, depend on pro-
tein kinases to transduce intracellular signals,3 highlighting the thera-
peutic potential of kinase inhibitors to treat inﬂammatory diseases.
Inﬂammatory bowel disease (IBD) is an umbrella term
primarily used to describe two conditions: Crohn’s disease and
ulcerative colitis (UC). Both diseases are characterized by recurrent
intestinal inﬂammation and epithelial injury believed to be initiated
by an inappropriate response to the gut microbiota.4,5 Interplay
between luminal antigens, inﬁltrating leukocytes, the epithelium,
and stromal cells results in excess production of proinﬂammatory
cytokines, such as tumor necrosis factor (TNF)-a, interleukin
(IL)-1b, IL-6, and IL-8.6 Cytokine production by these cells is
controlled by a diverse array of intracellular kinases. P38a, a mem-
ber of the P38 mitogen-activated protein kinase (MAPK) family,
has been reported to be the most important MAPK isoform in
inﬂammatory cells in the mucosa of patients with IBD.7,8 Being
a downstream kinase, P38a is a point of convergence for multiple
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inﬂammatory signaling pathways and therefore has garnered much
interest as a therapeutic target. In a phase III clinical trial, treatment
of patients with active Crohn’s disease with BIRB-796, a selective
P38 MAPK inhibitor, was associated with a dose-dependent
decrease in serum C-reactive protein after 1 week. However, com-
pared to placebo, no clinical efﬁcacy endpoints were reached at any
time point in the study.9 One explanation of the lack of efﬁcacy of
BIRB-796 may be redundancy in the signaling pathways, overrid-
ing the need for P38a in the inﬂammatory cascade. Potentially, this
could be avoided by targeting more upstream signaling nodes and
possibly several different targets simultaneously.10 Src family
kinase (SFK) members Lck and Fyn are among the ﬁrst upstream
kinases to be engaged upon T-cell receptor activation, and spleen
tyrosine kinase (Syk) is engaged early in B-cell receptor and Fc
receptor signaling.11 Neither SFK nor Syk has been a clinical target
for IBD; however, a selective Syk inhibitor, fostamatinib, has been
shown to decrease mucosal damage in a mouse acetic acid–induced
colitis model,12 and the key role T cells have in IBD pathogenesis
indicates merit in targeting SFK members. Furthermore, fostamati-
nib is a particularly promising treatment of chronic lymphocytic
leukemia13; however, it achieved only limited efﬁcacy in a phase III
rheumatoid arthritis trial,14 indicating that for inﬂammatory disor-
ders of more complex pathophysiology, single target inhibition may
not be sufﬁcient for clinical efﬁcacy.
Polypharmacology is emerging as the next paradigm of
drug discovery with a belief that targeting multiple signaling
nodes with a single drug may lead to improved efﬁcacy,
particularly in multifaceted diseases such as IBD and rheumatoid
arthritis.15 Initially, it was believed that a high degree of kinase
selectivity would be critical for an acceptable safety proﬁle with
concerns that systemic multikinase inhibition might increase the
risk of an adverse safety proﬁle. This has, however, been ad-
dressed through the proposal of topical delivery of kinase inhib-
itors.16,17 For example, pan-Janus kinase inhibitors are in
preclinical development as inhaled therapy for severe asthma.18
A class of narrow spectrum kinase inhibitors (NSKI) has
been developed, which target P38a, SFK, and Syk. Targeting these
kinases addresses the narrow window of activity achieved with truly
selective inhibitors and at the same time avoids potential signaling
redundancy as observed when targeting only downstream signaling
nodes. To et al19 recently described the superior effects of an NSKI,
RV1088, over selective kinase inhibitors in rheumatoid arthritis
synovial membrane cells. In this study, we investigated how another
NSKI, TOP1210, compares to selective kinase inhibitors, both in
terms of breadth of activity and pharmacology (efﬁcacy and
potency), across different inﬂammatory cell types, in selected
human cell assays and in tissue explants from patients with UC.
METHODS
Kinase Assays
A commercial 384-well ﬂuorescence resonance energy
transfer (FRET)-based kinase assay for Src, P38a, and Syk kinases
was used to measure inhibitory activity of compounds. Compound
or vehicle (dimethyl sulfoxide [DMSO], 1% v/v) was incubated
with kinase of interest (P38a, 20 ng/mL; Src, 750 ng/mL; or
Syk, 500 ng/mL) for 2 hours. Z-lyte peptide (Invitrogen, Paisley,
United Kingdom), selective for an individual kinase, was added
(Ser threonine 4 peptide for P38a, Tyr2 peptide for Src and
Syk). ATP, 10 mM, 200 mM, or 15 mM, for P38a Src and Syk,
respectively, was then added. In addition, inactive MAPK-activated
protein kinase (MAPKAP)2 (180 ng/mL) was added to the P38a
reaction mix. After 1 hour incubation, development reagent was
added followed by another 1 hour incubation. The reaction was
terminated and read using a ﬂuorescence microplate reader.
Patients and Samples
Peripheral venous blood from healthy volunteers was
collected by venepuncture and anticoagulated with ethylenedia-
minetetraacetic acid (EDTA). Perendoscopic biopsies or surgical
specimens were taken from macroscopically inﬂamed colonic
areas of patients with UC. Diagnosis of UC was made according
to clinical and histologic criteria and conﬁrmed by endoscopy.
Each patient or volunteer who took part in the study was recruited
after appropriate local ethics committee approval, and informed
consent was obtained in all cases.
Preparation of Human Peripheral Blood
Mononuclear Cells
Blood was diluted (1:1) with phosphate-buffered saline
(PBS)-containing EDTA (2 mM) before overlaying on Lympho-
prep. The sample was centrifuged (1200 · g, 20 min), and the
resultant “buffy coat” containing the peripheral blood mononu-
clear cells (PBMCs) was collected. After further centrifugation
(780 · g, 10 min) and washing (·2) in PBS containing EDTA
(2 mM), the ﬁnal cell pellet was resuspended in 10 mL PBS/
EDTA (2 mM). Cells were counted and the ﬁnal concentration
was adjusted to 1 · 106 cells per mL by resuspension in RPMI
1640 culture media containing heat inactivated fetal bovine serum
(FBS, 10% v/v), penicillin/streptomycin, and HEPES (25 mM).
Cellular Assays
Lipopolysaccharide Stimulation of PBMCs
PBMCs (200 mL) were incubated (2 hours, 378C, 5% CO2)
with test compound (0.1–1000 ng/mL) or vehicle (DMSO, 0.5% v/v).
Lipopolysaccharide (LPS, 1 ng/mL) was added, and after 24-hour
incubation (378C, 5% CO2), plates were centrifuged (780 · g, 2 min)
and supernatants were collected for analysis of IL-8 levels.
CD3/CD28 Stimulation of PBMCs
PBMCs (200 mL) were added to anti-CD3 (clone OKT3,
0.6 mg/mL) and anti-CD28 (clone CD28.2, 12 mg/mL) coated 96-
well plates. Test compound (0.1–1000 ng/mL) or vehicle (DMSO,
0.5% v/v) was added. After 72-hour incubation (378C, 5% CO2),
plates were centrifuged (780 · g, 2 min) before collection of
supernatants for analysis of IL-2 and interferon (IFN)-g levels.
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LPS Activation of Monocyte-derived Macrophages
CD14+ cells were isolated from human PBMCs by positive
selection using magnetic beads. Cells were resuspended in RPMI
containing 10% FBS and cultured (378C, 5% CO2) in the presence
of human recombinant granulocyte-macrophage colony-stimulating
factor (100 ng/mL) for 12 to 14 days. Cells were harvested and
resuspended (2 · 105 cells per mL), dispensed into 96-well plates
(100 mL/well) and allowed to equilibrate (2 hours). Test compound
(0.1–1000 ng/mL) or vehicle (DMSO 0.5% v/v) was incubated
with cells (2 h) before stimulation with LPS (10 ng/mL) for 24
hours. Supernatants were collected for IL-8 and TNF-a analysis.
IL-8 Production by HT29 Cells
HT29 cells, a colonic epithelial cell line, were seeded (2 · 105
cells per well) from established cultures onto 96-well plates in culture
media (McCoy’s 5a containing 10% FBS) and allowed to adhere for
24 hours. Test compound (0.1–1000 ng/mL) or vehicle (DMSO,
0.5% v/v) was added for 2 hours (378C, 5% CO2) before stimulation
by addition of recombinant human IL-1b (5 ng/mL). After further 24
hours (378C, 5% CO2), plates were centrifuged (195 · g, 5 min) and
supernatants were collected for measurement of IL-8.
In separate experiments, the potential cytotoxic effects of
compounds were assessed by incubation (378C, 24 h) of com-
pound or vehicle with HT29 cells seeded as above. Viability of
cells was assessed by addition of Presto blue and reading ﬂuores-
cence (560 nm/590 nm) after 10 to 30 minutes. At the chosen
concentrations of test compounds used in these studies, no signif-
icant decrease in viability was detected (data not shown).
Myoﬁbroblast Isolation and Culture
Intestinal myoﬁbroblasts were isolated from inﬂamed resected
UC mucosa. The mucosa was dissected from the submucosa with
a scalpel and cut into 1 mm square pieces. These were then cultured
at 378C in a humidiﬁed CO2 incubator in D-MEM medium, supple-
mented with 20% FBS, 100-U/mL penicillin, 100 mg/mL strepto-
mycin, 50 mg/mL gentamicin, and 1 mg/mL amphotericin.
Established colonies of myoﬁbroblasts were seeded into 25 cm2
culture ﬂasks and cultured in DMEM medium, supplemented with
20% FBS and antibiotics. At conﬂuence, the cells were passaged
using trypsin-EDTA in a 1:2 to 1:3 split ratios. Cells were grown to
at least passage 4 before use. Subconﬂuent monolayers of myoﬁ-
broblasts were seeded (5 · 104 cells/well) into 12-well plates and
cultured overnight at 378C, 5% CO2 before being stimulated with
20 ng/mL recombinant human TNF-a and either vehicle (DMSO,
0.5% v/v) or test compound (TOP1210, 0.000001–1 mg/mL; BIRB-
796, 0.01–10 mg/mL; dasatinib, 0.01–10 mg/mL; or BAY-61-3606,
0.01–10 mg/mL). After 24 hour culture, supernatants were collected
for measurement of IL-6 and IL-8 by enzyme-linked immunosor-
bent assay (ELISA). Results were expressed as mean percent inhi-
bition 6 SEM compared with TNF-a + DMSO.
Organ Culture
Inﬂamed biopsies from patients with UC were placed (one
biopsy per well) in 24-well plates in 300 mL serum-free HL-1
medium supplemented with 100 U/mL penicillin and 100 mg/mL
streptomycin, and cultured at 378C, 5% CO2 with either vehicle
(DMSO, 0.5% v/v) or test compound (TOP1210, 0.001–1 mg/mL;
1 mg/mL BIRB-796; 1 mg/mL dasatinib; or 1 mg/mL BAY-61-
3606), or selective kinase inhibitors in combination. After 24 hour
culture, supernatants of mucosal biopsies were collected for mea-
surement of IL-1b, IL-6, and IL-8 by ELISA. Results were
expressed as mean percent inhibition 6 SEM compared with
DMSO.
Enzyme-linked Immunosorbent Assay
All cytokines were measured using commercial ELISA kits
according to manufacturers’ instructions.
Materials and Reagents: TOP1210, BIRB-796,
Dasatinib, BAY61-3606
TOP1210, 3-((4-((4-(3-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-
5-yl)ureido)naphthalen-1 yl)oxy)pyrimidin-2-yl)amino)-5-ethynyl-
N-(2-(2-(2-methoxyethoxy)ethoxy)ethyl)benzamide, was prepared
employing published procedures.20 Dasatinib was supplied by LC
Laboratories (Woburn, MA), and BIRB-796 was obtained from
Ontario Chemicals Inc. (Ontario, Canada).
Z-lyte assay materials and heat-inactivated FBS were
obtained from Invitrogen (Paisley, United Kingdom). Lympho-
prep was obtained from Alere Ltd. (Stockport, Cheshire, United
Kingdom). Anti-CD3 and anti-CD28 antibodies were supplied by
eBioscience (Hatﬁeld, Hertfordshire, United Kingdom) and BD
Bioscience (Cowley, Oxford, United Kingdom), respectively.
ELISA kits were obtained from R&D systems (Abingdon, United
Kingdom). All other reagents were obtained from Sigma-Aldrich
(Gillingham, Dorset, United Kingdom).
Statistical Analysis
Data were analyzed using GraphPad Prism (GraphPad
Software, San Diego, CA) using the one-way analysis of variance
followed by the Dunnett’s multiple-comparisons test or the Krus-
kal–Wallis test followed by the Dunn’s multiple-comparisons test.
A level of P , 0.05 was considered statistically signiﬁcant.
RESULTS
Inhibition of Key Kinases
The inhibitory activity of TOP1210 and selective kinase
inhibitors was assessed in an ATP-dependent substrate phosphor-
ylation assay (Table 1). The selective kinase inhibitors chosen for
this study were BIRB-796 (p38 MAPK inhibitor), dasatinib (SFK
inhibitor), and BAY-61-3606 (Syk inhibitor). Inhibition of Src
was considered to be representative of effects on SFK because
of the high level of homology within this kinase family. TOP1210
treatment achieved potent, concentration-related inhibition of
p38a, Src, and Syk kinase activities with IC50 values of 65, 10,
and 17 nM, respectively. In contrast, BIRB-796 and BAY-61-
3606 only inhibited their respective kinase targets. Dasatinib
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potently inhibited Src kinase activity (IC50, 6 nM) but was also
a weak inhibitor of p38a (IC50, 378 nM). TOP1210 potency was
comparable to (IC50, within 5-fold) or, in the case of BAY-61-
3606, greater than that of the selective kinase inhibitors at their
respective target kinase.
Effect of TOP1210 and Selective Kinase
Inhibitors on Innate, Adaptive, and Epithelial
Cellular Responses
Mucosal inﬂammation involves the interplay of innate and
adaptive immune mechanisms with the epithelium. As a model of
innate immunity, PBMCs were stimulated with LPS, leading to
IL-8 release (15,658 6 1500 pg/mL, mean 6 SEM). TOP1210
achieved concentration-dependent (0.1–1000 ng/mL) and maxi-
mal (100%) inhibition of IL-8 release (Fig. 1A) with an IC50 value
of 1.9 nM (Table 2). In contrast, both BIRB-796 and dasatinib
failed to achieve 50% inhibition at any concentration up to the
maximum tested (1 mg/mL). BAY-61-3606 achieved a maximum
of 83% inhibition but with a potency (IC50 607 nM, Table 2)
some 300-fold weaker than TOP1210. A similar proﬁle was
observed in LPS-stimulated primary human macrophages with
TOP1210 demonstrating superior activity over the selective inhib-
itors, achieving potent, maximal inhibition of IL-8 (Fig. 1B) and
TNF-a release (Fig. 1C) with IC50 values of 2.2 and 3.3 nM,
respectively (Table 2). BIRB-796 and BAY-61-3606 failed to
achieve 50% inhibition of either IL-8 or TNF-a at any concentra-
tion up to the maximum tested (250 ng/mL). Dasatinib achieved
87% inhibition of TNF-a release but was approximately 30-fold
weaker (IC50, 52 nM, Table 2) than TOP1210 and achieved less
than 50% inhibition of IL-8 release.
To model the adaptive immune response, PBMCs were
stimulated with anti-CD3 and anti-CD28 to activate the T-cell
population. This stimulation led to release of IFN-g (16,146 6
5926 pg/mL, mean 6 SEM) and IL-2 (39,742 6 9652 pg/mL,
mean 6 SEM). TOP1210 achieved maximal inhibition of IFN-g
release (Fig. 2A) with an IC50 of 2.1 nM (Table 2). As expected,
the SFK selective inhibitor, dasatinib, was also a potent inhibitor
of IFN-g release with similar potency (IC50, 4.0 nM, Table 2) to
that of TOP1210. BIRB-796 was inactive in the assay, and BAY-
61-3606, although achieving maximal efﬁcacy, was 120-fold
weaker (IC50, 247 nM) than TOP1210. In the IL-2 release assay,
a very similar proﬁle was observed with the selective kinase in-
hibitors (Fig. 2B). TOP1210, however, was 18-fold weaker in
potency as an inhibitor of IL-2 release (IC50, 37 nM, Table 2)
compared with IFN-g release.
Inﬂammation of the epithelium is a hallmark of many mucosal
disorders. Because of the difﬁculty of culturing primary human
colonic cells, HT29 cells, a human intestinal epithelial cell line, has
been used as a model of human colonic epithelium. Stimulation of
TABLE 1. Inhibitory Effects of Selective Kinase
Inhibitors and the NSKI TOP1210 on p38a, Src, or Syk
Kinase Activity in a Biochemical Z-lyte Based Assay
Kinase Assay IC50 Value, nM
p38a Src Syk
TOP1210 65 10 17
BIRB-796 13 .1895 .1895
Dasatinib 378 6 .2049
BAY-61-3606 .2562 .2562 136
TOP1210 potently inhibits all kinases tested, whereas BIRB-796, dasatinib, and BAY-61-
3606 show selective proﬁles. Table shows geometric mean IC50 values (nM) from at least
3 independent experiments.
FIGURE 1. TOP1210 is a potent inhibitor of the innate immune responses in LPS-stimulated human PBMCs and macrophages. TOP1210 inhibits
IL-8 release by LPS-stimulated PBMCs (A) and macrophages (B), and also LPS-stimulated TNF-a release by macrophages (C), with greater potency
than any of the selective kinases tested. Generally, compared to TOP1210, BIRB-796, dasatinib, and BAY61-3606 have weak potency and efﬁcacy in
both PBMCs and macrophages. Graphs represent means of at least 3 independent experiments 6 SEM.
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these cells with IL-1b leads to IL-8 release levels of 1736 6 93 pg/
mL (mean 6 SEM). TOP1210 potently (IC50, 1.8 nM, Table 2)
inhibited IL-8 release with maximal efﬁcacy (Fig. 3). In contrast,
all three selective kinase inhibitors were only weakly active in the
assay with none achieving greater than 50% inhibition.
In a propidium iodide, ﬂow cytometry–based assay,
TOP1210 was shown not to effect cell viability at any of the
concentrations tested in the cellular assays (data not shown).
In summary, TOP1210 was potent and highly efﬁcacious
across all cellular models of innate, adaptive, and epithelial
responses. In contrast, the selective kinase inhibitors of P38a,
SFK, and Syk were only active in some assays and for the most
part much less potent than TOP1210.
Effect of Selective Kinase Inhibitor
Combination on IL-8 Release by HT29 Cells
BIRB-796 (0.1–1000 ng/mL) produced concentration-
dependent inhibition of IL-8 secretion from IL-1b–stimulated
HT29 epithelial cells (Fig. 4A) with a maximum inhibition of
33%. Dasatinib and BAY-61-3606 when tested alone had a similar
inhibitory proﬁle, achieving maximal inhibitions at 1000 ng/mL
of 22% and 17%, respectively (Fig. 4A). Neither dasatinib nor
BAY-61-3606 had any signiﬁcant inhibitory effect at 100 ng/mL
(Fig. 4A). In combination with BIRB-796, however, both 100-
ng/mL dasatinib and 100 ng/mL BAY-61-3606 induced a leftward
shift of the BIRB-796 concentration effect curve and increased the
maximum inhibition to approximately 50% (Fig. 4B). A triple
TABLE 2. Effect of TOP1210 and Selective Kinase Inhibitors on Innate (LPS Stimulation of PBMCs or Primary
Macrophages), Adaptive (Anti-CD3/Anti-CD28 Stimulation of PBMCs), and Epithelial (IL-1b Stimulation of HT29
Cells) Cellular Response Assays
IC50 Value, nM
Innate Response: Monocytes Adaptive Response: T Cells Epithelium
PBMCs Primary Macrophages PBMCs PBMCs HT29 Cells
IL-8 Release IL-8 Release TNF-a Release IL-2 Release IFN-g Release IL-8 Release
TOP1210 1.9 2.2 3.3 37 2.1 1.8
BIRB-796 .1895 .250 .474 .1895 .1895 .1895
Dasatinib .2049 .250 52 2.1 4.0 .2049
BAY-61-3606 607 .250 .640 291 247 .2561
Data show geometric mean IC50 values (nM) achieved compared with vehicle (DMSO)-treated controls from a minimum of 3 determinations.
FIGURE 2. TOP1210 is a potent inhibitor of an adaptive immune response in anti-CD3/anti-CD28–stimulated T-cell release of IFN-g (A) and IL-2 (B).
Both TOP1210 and dasatinib inhibit IFN-g release with similar potency, whereas TOP1210 is approximately 15-fold weaker than dasatinib as an
inhibitor of IL-2 release. BAY61-3606 demonstrates weaker inhibition, whereas BIRB-796 has little-to-no effect. Graphs represent means of at least
3 independent experiments 6 SEM.
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combination of BIRB-796, 100 ng/mL dasatinib, and 100 ng/mL
BAY-61-3606 induced a further leftward shift and increased the
maximum inhibition to 63% (Fig. 4B). A more than additive effect
is illustrated in Fig. 4C, where the combination of noninhibitory
concentrations of BIRB-796 (1 ng/mL), dasatinib (100 ng/mL),
and BAY-61-3606 (100 ng/mL) results in 30% inhibition of IL-8
secretion.
Effect of TOP1210 and Selective Kinase
Inhibitors on Proinﬂammatory Cytokine
Release by UC Myoﬁbroblasts
Myoﬁbroblasts isolated from inﬂamed UC mucosa were used
to compare the anti-inﬂammatory activity of TOP1210 to that of
selective kinase inhibitors. Vehicle (DMSO) treated myoﬁbroblasts,
after TNF-a stimulation, released IL-6 and IL-8 levels of 14,740 6
6518 pg/mL and 49,363 6 15,694 pg/mL (means 6 SEM), respec-
tively. TOP1210 achieved concentration-dependent inhibition of both
IL-6 (IC50, 2.2 ng/mL) and IL-8 (IC50, 2.1 ng/mL) production by UC
myoﬁbroblasts (Fig. 5, Table 3). BIRB-796 required 1 mg/mL to
signiﬁcantly reduce both IL-6 and IL-8 release with a maximum
inhibition of only 70% achieved. Moreover, dasatinib (0.1–
10 mg/mL) signiﬁcantly reduced IL-6 release in a concentra-
tion-dependent manner by approximately 36% to 60%, and
10 mg/mL dasatinib signiﬁcantly inhibited IL-8 by approxi-
mately 70%. Finally, BAY-61-3606 was the most active of
the selective kinase inhibitors in this assay, signiﬁcantly
reducing both IL-6 and IL-8 release with efﬁcacy of over
90%, however, at a weaker potency compared with TOP1210.
Although the selective kinase inhibitors reduced both IL-6 and
IL-8 release from UC myoﬁbroblasts, in all cases, they were
signiﬁcantly less potent than TOP1210 (Table 3), and in most
cases, maximum efﬁcacy was much reduced compared with
TOP1210 (Fig. 5).
Effect of TOP1210 and Selective Kinase
Inhibitors Alone or in Combination with
Proinﬂammatory Cytokine Release by
UC Biopsies
Biopsies from patients with IBD can be used as an
inﬂammatory model of disease21 and have been shown here to
spontaneously release high levels of proinﬂammatory cytokines
(IL-1b, 459 6 124 pg/mL; IL-6, 18,428 6 4847 pg/mL; and IL-8
67,155 6 13,377 pg/mL [means 6 SEM]). TOP1210 and selec-
tive kinase inhibitors at 1 mg/mL were proﬁled in an organ culture
assay using inﬂamed colonic biopsies from patients with UC.
TOP1210 signiﬁcantly inhibited IL-1b, IL-6, and IL-8 release
from inﬂamed UC biopsies by 80% to 90% (Fig. 6A, B). BAY-
61-3606 and BIRB-796 also signiﬁcantly inhibited release of all
three cytokines (50%–65% inhibition), but with a reduced effect
compared with TOP1210. Dasatinib did not have any signiﬁcant
effect on IL-1b, IL-6, and IL-8 release from the UC biopsies.
When the three selective kinase inhibitors were combined, the
level of inhibition produced against all 3 cytokines was similar
to that for TOP1210 (Fig. 6A). Moreover, TOP1210 inhibited IL-
1b, IL-6, and IL-8 release by UC biopsies in a concentration-
dependent manner (Fig. 6B).
DISCUSSION
Selective kinase inhibitors to date have been disappointing
in the treatment of inﬂammatory disorders, particularly in
rheumatoid arthritis and IBD.9,14 Consequently, attention has
turned to multikinase inhibition in an attempt to improve efﬁ-
cacy by targeting a broader range of cell types and cytokines. In
this study, TOP1210 has been compared to selective kinase in-
hibitors (BIRB-796, dasatinib, and BAY-61-3606) in a range of
inﬂammatory cell assays and in inﬂamed biopsies from patients
with UC.
TOP1210 potently inhibits p38a, SFK, and Syk kinases and
is comparable or higher in potency than each of the selective
inhibitors at their relevant kinase. The limited anti-inﬂammatory
proﬁle of each of the selective kinase inhibitors can, in part, be
explained by both the relative expression of their target kinases in
selected cell types and the participation of speciﬁc kinases in
signaling pathways associated with the stimuli used in the cell
assay. P38a and the Src family members, Src, Fyn, and Yes, are
ubiquitously expressed in a broad range of stromal and hemato-
poietic cells, whereas the expression of other SFK members (Lck
and Hck) and Syk is restricted to hematopoietic cells. It is, per-
haps, unsurprising that inhibition of Syk by BAY-61-3606 results
in poor efﬁcacy in the innate cell assays given that the LPS
stimulation acts through TLR4 signaling pathway, which does
not involve Syk. Conversely, although P38a is ubiquitously
FIGURE 3. TOP1210 is a potent inhibitor of IL-1b–stimulated IL-8
release from HT29 cells. Selective kinase inhibitors achieve less than
50% inhibition and are weak inhibitors of IL-8 release from HT29 cells.
Graph represents means of at least 3 independent experiments 6
SEM.
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expressed and involved in most signaling cascades tested, its
selective inhibition by BIRB-796 failed to achieve even 50%
inhibition in any of the cellular assays. P38a is involved in down-
stream signaling, and redundancy at this level may explain lack of
efﬁcacy, which has indeed been alluded to an explanation of the
disappointing results with BIRB-796 in clinical studies.10 In
macrophages, the effects of SFK inhibition with dasatinib ap-
peared to be cytokine dependent with relatively potent inhibition
of TNF-a achieved compared with the poor activity against IL-8
release. In contrast, the multikinase inhibitory proﬁle of
TOP1210 results in potent inhibition of both IL-8 and TNF-a
in these innate responses from monocytes and macrophages,
respectively. If we consider the adaptive responses, the impor-
tance of SFK members Lck and Fyn in T-cell receptor signaling
helps to explain the potent and efﬁcacious inhibition achieved
with dasatinib. The potent activity of TOP1210 in these T-cell
assays is therefore most likely to be directly attributed to its
potent SFK inhibition. Collectively, TOP1210 achieves potent
inhibition across cellular models of both innate and adaptive
immunities, highlighting the broad acting anti-inﬂammatory
potential of the compound compared with selective kinase inhi-
bition. Interestingly, TOP1210 activity is far superior over the
individual selective inhibitors suggesting that there is added
beneﬁt in simultaneous targeting of P38a, SFK, and Syk, both
in efﬁcacy and breadth of effects across cell types particularly in
the case of IL-8 release.
Disruption of the epithelium is central to the development
of mucosal disorders, particularly in UC. As a consequence of
epithelial disruption, soluble mediators are released, for example,
IL-8, serving to recruit circulating neutrophils into the site of
inﬂammation. Interestingly, we demonstrate that the selective
kinase inhibitors are only weakly active in the IL-8 release assay,
yet TOP1210 is highly potent and efﬁcacious. A similar trend was
observed in the IL-8 release assay in monocytes, so the disparity
between TOP1210 and the selective inhibitors may be a cytokine,
rather than cell speciﬁc phenomenon. A range of inﬂammatory
cytokines is known to be key mediators of IBD, with IL-1b, IL-6,
IL-8, and IL-2 all being elevated in tissues from patients with
IBD.6 IL-8, however, seems of particular importance in UC as
serum levels of IL-8 correlate with disease activity.22 In this study,
we have demonstrated that TOP1210 potently inhibits IL-8 secre-
tion from monocytes, epithelial cells, UC myoﬁbroblasts, and UC
biopsies, yet interestingly, the selective kinase inhibitors individ-
ually were, at best, only weakly active.
To investigate this further, the IL-8 release assay in HT29
epithelial cells was used to study the effects of selective inhibitor
combinations. Individually, the selective kinase inhibitors achieve
poor inhibition. However, combination studies demonstrate that
the effects of inhibiting p38a with BIRB-796 can be augmented in
a more than additive manner by concomitant inhibition of SFK
and/or Syk using the appropriate selective kinase inhibitors. The
more than additive inhibitory effects are best demonstrated when
FIGURE 4. Combination of selective kinase inhibitors leads to more than additive inhibitory effects in reducing IL-8 secretion from
IL-1b–stimulated HT29 cells. BIRB-796, BAY-61-3606, and dasatinib individually induce concentration-dependent inhibition of IL-8 secretion but
with limited efﬁcacy (A). BIRB-796 in combination with BAY-61-3606 (100 ng/mL) and/or dasatinib (100 ng/mL) produces concentration-
dependent inhibition of IL-8 secretion with improved efﬁcacy and potency (B). Compared to the lack of effect of the same concentrations when
used individually, BIRB-796 (1 ng/mL)/BAY-61-3606 (100 ng/mL)/dasatinib (100 ng/mL) combination treatment is effective in reducing IL-8
concentration in a more than additive manner (C). Graphs represent means of at least 3 independent experiments 6 SEM.
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considering concentrations that, individually, are without inhibi-
tory effect. On combination, these concentrations bring about
augmented inhibition, albeit limited (approximately 30%). The
more than additive effects of noninhibitory concentrations of da-
satinib and BAY-61-3606 result in both increased potency (as
seen by leftward shifts of BIRB-796 concentration–effect curve)
and improved efﬁcacy of BIRB-796. These combination studies
demonstrate that simultaneous inhibition of P38a, SFK, and Syk
is a key to achieving highly potent inhibitory effects and suggest
that the effects achieved in HT29 cells with TOP1210 are most
likely mediated through the inhibition of the optimized targets
P38a, SFK, and Syk. In this investigation, IL-1b was used as
a stimulus of HT29 cells; however, in UC, a wide range of inﬂam-
matory stimuli may be acting on the epithelial cells, with numer-
ous pathways being activated and more kinases being involved. In
these circumstances, multikinase inhibition may be even more
beneﬁcial.
Although extensive combination experiments could not be
performed with UC biopsies because of limited availability of
tissue, the data generated with the organ culture model support the
more than additive effects observed in the combination studies in
HT29 cells. The broad inhibitory actions of TOP1210 across
FIGURE 5. TOP1210 is more potent than selective kinase inhibitors in downregulating proinﬂammatory cytokine release from TNF-a–stimulated
UC mucosal myoﬁbroblasts. Effect of different concentrations of TOP1210, BIRB-796 (BIRB), dasatinib (DAS), or BAY-61-3606 (BAY) on the release of
IL 6 and IL-8, expressed as mean percent inhibition compared with stimulated control (DMSO; 20-ng/mL recombinant human TNF-a + DMSO, 0.5%
v/v). Bars represent mean 6 SEM of at least 3 independent experiments. *P , 0.01 versus stimulated control; **P , 0.001 versus stimulated
control.
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a range of cell types translated to potent and efﬁcacious effects on
cytokine release from inﬂamed UC colonic biopsies. TOP1210
inhibited, in a concentration dependent manner, all the cytokines
measured, namely, IL-1b, IL-6, and IL-8, and had superior
efﬁcacy compared with the selective kinase inhibitors at equiva-
lent concentrations.
UC is a complex disease characterized by recurrent
episodes of colonic inﬂammation involving immune and non-
immune cells, and also the colonic epithelium.23 In addition to
a T-cell response, the inﬂammatory process in UC involves gross
epithelial cell changes, and macrophage and neutrophil inﬁltration
driven by an array of inﬂammatory cytokines.5 Many approaches
targeting a single cytokine or cell type seem to have limited
efﬁcacy, or development has been stopped because of toxic ef-
fects.6 Conversely, a therapeutic approach that targets multiple
cellular pathways and mechanisms is more likely to be effective.24
These studies have shown that the NSKI TOP1210 leads to
a broad proﬁle of inﬂammatory cell inhibition with greatly
enhanced effects over those of selective kinases. Recently, tofa-
citinib, an oral pan-Janus kinase inhibitor, has been effective in
a clinical trial in UC.25,26 Primarily targeting T cells, this has
shown promise but has generally been limited in dose because
FIGURE 6. TOP1210 is superior to selective kinase inhibitors alone in downregulating proinﬂammatory cytokine release from UC biopsies.
TOP1210 activity is comparable to a combination of all three selective inhibitors and reduces proinﬂammatory cytokine release from UC biopsies
in a concentration-dependent manner. Effect of 1 mg/mL TOP1210, 1 mg/mL BIRB-796 (BIRB), 1 mg/mL dasatinib (DAS), and 1 mg/mL BAY-61-3606
(BAY), or the combination of the 3 selective kinase inhibitors (A) or TOP1210 (0.001–1 mg/mL) (B) on the release of IL-1b, IL-6, and IL-8, expressed
as mean percent inhibition compared with control (DMSO; DMSO, 0.5% v/v), in organ culture supernatants of inﬂamed colonic biopsies
from patients with UC. Bars represent mean 6 SEM of at least 3 independent experiments. *P , 0.05 versus DMSO; **P , 0.005 versus DMSO;
***P , 0.0005 versus DMSO.
TABLE 3. Inhibitory Effects of the NSKI TOP1210 and
the Selective Kinase Inhibitors on Proinﬂammatory
Cytokine Release by UC Myoﬁbroblasts
IL-6 (IC50 Value, ng/mL) IL-8 (IC50 Value, ng/mL)
TOP1210 2.2 2.1
BIRB-796 .1000 .1000
Dasatinib .1000 .1000
BAY-61-3606 315 630
Table shows mean IC50 values (ng/mL) from at least 3 independent experiments.
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of toxic side effects, in the same manner as other systemic kinase
inhibitor approaches. Nevertheless, there may be opportunities to
capitalize on the promise shown, for example, by further optimiz-
ing targets or by restricting systemic exposure through topical
administration.
In summary, selective kinase inhibitors demonstrate limited
efﬁcacy and potency and individually have activity only in
selected cell types. In contrast, TOP1210, through multikinase
inhibition, demonstrates potent, efﬁcacious, and broad inhibitory
activity in UC tissues and across a range of cell types including
epithelial cells, innate, and adaptive immune cells. These studies
suggest that the inhibition of multiple kinases, either though
combined selective kinase inhibitors or by NSKI TOP1210,
results in more than additive anti-inﬂammatory effects. The broad
efﬁcacy proﬁle of TOP1210 offers signiﬁcant advantages over
existing selective kinase approaches and potentially offers a much
improved therapeutic beneﬁt in IBD.
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